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We thank Dr Alatorre and co-authors for their letter [1]
regarding our manuscript entitled ‘‘Cost effectiveness of
guanfacine extended-release versus atomoxetine for the
treatment of attention-deficit/hyperactivity disorder: appli-
cation of a matching-adjusted indirect comparison’’, which
was published in the November 1, 2012 issue of Applied
Health Economics and Health Policy [2].
We have conducted a thorough review of the manuscript
and supportive study analyses from which it stems. We
have found that some numbers in Table III were transposed
in the published manuscript. The erratum [3] is published
to correct these errors.
We apologize for the errors and confirm that these errors
are typographical in nature and do not affect the results,
discussion or conclusion in the originally published man-
uscript [2].
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
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